Article

Comorbidities Related to Pediatric ADHD May Be Characterized Using CBCL

Author(s):

The Child Behavior Checklist may provide invaluable information to clinicians regarding the type and severity of comorbid psychopathologies.

Joseph Biederman, MD

Joseph Biederman, MD

The Child Behavior Checklist (CBCL) may be useful in characterizing comorbidity in children referred to a clinician for ADHD.

Findings presented at the 2021 American Professional Society of ADHD and Related Disorders (APSARD)Virtual Meeting demonstrated that a majority of clinically referred children with suspected ADHD also presented with comorbid psychopathology.

Further, these comorbidities were measured according to the CBCL’s individual and composite clinical scales.

A team led by Joseph Biederman, MD, Chief, Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital, evaluated whether or not the CBCL would be useful in characterizing such comorbid psychopathy.

They acknowledged that assessment of ADHD-related comorbidity in clinical practice has long been lacking in research.

“Previous research documented excellent convergence between the CBCL and DSM-based disorders,” Biederman and colleagues wrote. 

“Because it is a simple to use, parent completed questionnaire assessing various dimensions of psychopathology, it facilitates the characterization of comorbid psychopathology in children with ADHD in clinical practice,” they continued.

The Study

The team thus assessed a sample consisting of 332 newly referred children 4-18 years of age. All patients were identified with suspected ADHD, defined as having CBCL Attention Problems T-scores ≥60, for example.

Using the CBCL, the investigators evaluated additional psychopathology through examination of abnormal T-scores on individual, composite, and unique profile scales. These scores were considered proxies for additional comorbid disorders.

Thus, they found that 76% of these children had ≥3 additional abnormal CBCL scales, which further suggests a likelihood that they were affected with other comorbid psychiatric disorders.

“Moreover, 44% of youth with suspected ADHD had at least one other CBCL clinical scale with a T-score more severe (≥0.5 standard deviation higher) than their CBCL Attention Problems T-score,” the team wrote.

According to their results, 13% of patients had the Anxious/Depressed scale as their most severe scale, while 11% had the Aggressive Behavior scale as their most severe scale, and 8% had the Withdrawn/Depressed scale has their most severe scale.

The investigators noted few differences between male and female as well as children and adolescents.

As such, the CBCL provided relevant information about the types and severity of suspected psychopathological conditions that may affect youth. This information can then be useful in guiding clinicians in their assessment of differing clinical and therapeutic needs of their patients. 

“These findings have implications for the clinical care of youth with ADHD and for improved consideration of the complexity of clinical presentations of children with ADHD in any clinical setting,” Biederman and colleagues wrote.

The study, “Can the Child Behavior Checklist Characterize Comorbidity in Clinically Referred Youth With ADHD?” was presented at APSARD 2021.

Related Videos
Ben Samelson-Jones,Ben Samelson-Jones, MD, PhD: Validating Long-Term Safety of Hemophilia AAV Gene Therapy MD, PhD: Validating Long-Term Safety of Hemophilia AAV Gene Therapy
Françoise Bernaudin, MD: A Decade of Follow-up Reveals allo-SCT Superiority Over SOC for Sickle Cell Anemia
Achieving Quick Responses in Sickle Cell Anemia With Early, Appropriate Hydroxyurea Dosing, with Abena Appiah-Kubi, MD, MPH
Steven W. Pipe, MD: Fitusiran With Anti-Thrombin Modulation Yields Effective Bleed Control, Reduces Infusions
Caroline Piatek, MD: Improving Patient-Reported Outcomes in PNH With Danicopan Add-on Therapy
Haydar Frangoul, MD: Preventing VOCs in People With Sickle Cell Disease With Exa-Cel Gene Editing Therapy
Jörn Schattenberg, MD | Credit: Novo Nordisk
Jörn Schattenberg, MD | Credit: Novo Nordisk
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
© 2024 MJH Life Sciences

All rights reserved.